All News Nanexa AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 16:24:09 13/05/2024 BST			5-day change	1st Jan Change
0.88 ^SEK	+4.76%		+18.92%	-28.46%

05-03	Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-16	Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	CI

Nanexa Q1 2024 - Insightful capital markets day	05-10	AQ
Equity Research \| NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential	05-10	AQ
Nanexa publishes interim report for January-March 2024	05-03	AQ
Nanexa AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-03	CI
Invitation to comment on Nanexa's Q1 report 2024	04-30	AQ
Nanexa invites to Capital Markets Day on May 7	04-29	AQ
Approval of clinical trial application for NEX-22 study delayed	04-16	AQ
Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed	04-16	CI
Notice of annual general meeting in Nanexa AB (publ)	04-15	AQ
Nanexa publishes annual report for 2023	03-27	AQ
Transcript : Nanexa AB - Special Call	03-07
Nanexa - NEX-22, partner projects, and Novo Nordisk evaluation prioritized	02-22	AQ
Equity Research \| NANEXA: Focus on dual GLP-1 opportunities and the partner projects	02-22	AQ
Nanexa publishes year-end report and Q4 report 2023	02-21	AQ
Nanexa AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-21	CI
Invitation to presentation of Nanexa's year-end report and Q4 report 2023	02-20	AQ
Equity Research \| NANEXA: Lining up to make Nanexa (close to) a pure GLP-1 play	12-21	AQ
Nanexa’s clinical trial application for NEX-22 Phase I study assessed by EMA	12-20	AQ
Nanexa AB Announces Clinical Trial Application for NEX-22 Phase I Study Assess by EMA	12-20	CI
Nanexa optimizes business operations through tactical priorities	12-20	AQ

No results for this search